Lawrence G. Lum

Professor of Medicine

University of Virginia
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (12)

Tumor clearance by T cells is impaired by insufficient tumor antigen recognition, insufficient tumor infiltration, and the immunosuppressive tumor microenvironment. Although targeted T cell therapy circumvents failures in tumor antigen recognition, suppression by the tumor microenvironment and failure to infiltrate the tumor can hinder tumor clearance. Checkpoint inhibitors (CPIs) promise to reverse T cell suppression and can be combined with bispecific antibody armed T cell (BAT) therapy to improve clinical outcomes. We hypothesize that adoptively transferred T cell function may be improved by the addition of CPIs if the inhibitory pathway is functionally active. This study develops a kinetic-dynamic model of killing of hormone receptor–positive breast cancer cells mediated by BATs using single-cell transcriptomic and temporal protein data to identify T cell phenotypes and quantify inhibitory receptor expression. LAG3, PD-1, and TIGIT were identified as inhibitory receptors expressed by cytotoxic effector CD8 BATs upon exposure to hormone receptor–positive breast cancer cell lines. These data were combined with real-time tumor cytotoxicity data in a multivariate statistical analysis framework to predict the relevant contributions of T cells expressing each receptor to tumor reduction. A mechanistic kinetic-dynamic mathematical model was developed and parametrized using protein expression and cytotoxicity data for in silico validation of the findings of the multivariate statistical analysis. The model corroborated the predictions of the multivariate statistical analysis which identified LAG3+ BATs as the primary effectors, while TIGIT expression dampened cytotoxic function. These results inform CPI selection for BATs combination therapy and provide a framework to maximize BATs antitumor function.

Year:

2025

Background Polyclonal autologous T cells that are epigenetically reprogrammed through mTOR inhibition and IFN-α polarization (RAPA-201) represent a novel approach to the adoptive T cell therapy of cancer. Ex vivo inhibition of mTOR results causes a shift towards T central memory (T CM ) whereas ex vivo IFN-α promotes type I cytokines, with each of these functions known to enhance the adoptive T cell therapy of cancer. Rapamycin-resistant T cells polarized for a type II cytokine phenotype were previously evaluated in the allogeneic transplantation context. Methods The clinical trial ( NCT04176380 ) evaluated RAPA-201 therapy in combination with fludarabine-sparing low-dose host conditioning for the treatment of patients with relapsed, refractory multiple myeloma (RRMM). Results From December 2020 to December 2022, 14 patients with RRMM received a median of three RAPA-201 infusions (median dose, 80×10 6 cells). RAPA-201 drug products (DPs) were: polyclonal; enriched for T CM cells; reduced for immune checkpoint expression, including PD1, CD73, and LAIR1; and preferentially secreted Th1 cytokines. The median chemotherapy dose administered per cycle was 1,817 mg total for cyclophosphamide (range, 1,100–2,200) and 2.35 mg/M 2 for pentostatin (range, 0–16). Nine of 14 patients (64%) achieved disease remission, with eight partial responses and one stringent complete response. Median progression-free survival was 6.0 months (range, 2.1 to>16.8 months). There were no toxicities of any grade attributable to RAPA-201, including no cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome. Only 4 of 14 patients (29%) had a serious adverse event (≥ grade 3) of any attribution. Conclusions Consistent with our hypothesis, ex vivo manufacturing using mTOR inhibition and IFN-α polarization consistently yielded a novel RAPA-201 DP that possessed a desirable phenotype relative to cytokine phenotype, memory status, and checkpoint expression. RAPA-201 recipients had preservation of T cell counts and Th1 cytokine secretion yet had increased T cell receptor clonality that associates with antitumor responses in the setting of monoclonal antibody checkpoint therapy. RAPA-201 therapy overcomes previous barriers to effective autologous polyclonal T-cell therapy, as it is feasible to manufacture, exquisitely safe to administer, and mediates remission in patients with RRMM. Trial registration number ClinicalTrials.gov: NCT04176380 .

Year:

2025

A and B. Evaluation of Vβ repertoire. The three distinct patterns were observed for Vβ repertoire in CD3+/IFN-γ+ T cells post IT. Pattern 1) the proportions of Vβ repertoire noticeably higher after IT relative to preIT PBMC (solid black arrows); Pattern 2) the proportions of Vβ repertoire that were marginally higher at mid- and/or post-IT relative to pre-IT PBMC (dashed black arrows); Pattern 3) large proportions of Vβ repertoire were either lower or similar at mid-IT or post-IT relative to preIT PBMC in all four patients tested. PreIT (pretherapy), midIT (preinfusion 5) postIT (1 week post infusion 8 of BATs).

Year:

2025

A-C. FFPE sections of PC were stained by multiplex staining panel for CD4, CD8, FoxP3 (T regulatory cells), CD19 (B cells), CD68 (macrophages). Stained sections were imaged on the Hamamatsu slide scanner NanoZoomer S360 and images were viewed on the NDP viewer software. Analysis of images were performed on online Visiopharm software. Using the low power image, high-powered Fields (HPFs) were selected from specific tumor regions. Data shows the distribution of CD4+ (teal), CD8+ (purple), FoxP3 (brown), CD19+ (green) and CD68+ (yellow) cells on two representative whole scanned slide images (KCI 04 and KCI 11) are shown. Top panel shows whole scanned tumor sections, inset 1 and 2 are shown below at high magnification (40x). B and C) Show the second set of serial sections of tumor specimens stained for IFN-γ and IL-10 from two patients shown in the upper panel, both IFN-γ (brown) and IL-10 (brown) were stained individually.

Year:

2025

Tumor clearance by T cells is impaired by insufficient tumor antigen recognition, insufficient tumor infiltration, and the immunosuppressive tumor microenvironment (TME). Although targeted T cell therapy circumvents failures in tumor antigen recognition, suppression by the TME and failure to infiltrate the tumor can hinder tumor clearance. Checkpoint inhibitors (CPI) promise to reverse T cell suppression and can be combined with bispecific antibody armed T cell (BATs) therapy to improve clinical outcomes. We hypothesize that adoptively transferred T cell function may be improved by the addition of CPI if the inhibitory pathway is functionally active. This study develops a kinetic-dynamic model of killing of hormone receptor-positive (HR+) breast cancer cells mediated by BATs using single-cell transcriptomic and temporal protein data to identify T cell phenotypes and quantify inhibitory receptor expression. LAG3, PD-1, and TIGIT were identified as inhibitory receptors expressed by cytotoxic effector CD8 BATs upon exposure to HR+ breast cancer cell lines. These data were combined with real-time tumor cytotoxicity data in a multivariate statistical analysis framework to predict the relevant contributions of T cells expressing each receptor to tumor reduction. A mechanistic kinetic-dynamic mathematical model was developed and parametrized using protein expression and cytotoxicity data for in silico validation of the findings of the multivariate statistical analysis. The model corroborated the predictions of the multivariate statistical analysis which identified LAG3+ BATs as the primary effectors, while TIGIT expression dampened cytotoxic function. These results inform CPI selection for BATs combination therapy and provide a framework to maximize BATs anti-tumor function. What is already known on this topic Bispecific antibody armed T cell (BATs) therapies are adoptive T cell therapies that can effectively reroute T cell cytotoxicity toward cancerous cells, but lack consistent and durable anti-tumor responses. Checkpoint proteins expressed on the surface of activated T cells dampen immune responses and can be overstimulated in solid tumors to hamper tumor clearance by T cells. Checkpoint inhibitor drugs can improve T cell anti-tumor response by blocking checkpoint protein signaling but are only effective if the targeted checkpoint protein is expressed on the T cell and activated in the tumor microenvironment, highlighting an opportunity to enhance BAT efficacy by combining treatment with synergistic CPI. What this study adds This study characterizes dynamic, time-resolved patterns in checkpoint protein expression by breast cancer-targeting adoptive T cells and predicts the significance of high-prevalence checkpoint proteins on T cell function. It also demonstrates the use of multivariate statistic and mathematical modeling toward rational design of targets and timing strategies for synergistic combination therapies. How this study might affect research, practice, or policy The output of this study provides justification for therapeutic strategies combining adoptive T cell therapies with checkpoint inhibitor drugs targeting TIGIT and LAG3 as a means of improving patient responses in HER2−/HR+ breast cancers.

Year:

2025

IFN-β induction after TLR1/2 stimulation associates with PBMC ELISpot responses to Fluzone, PHA, and CEFT (cytomegalovirus, EBV, Fluzone, and Tetanus peptide pool). A, ELISpot SFU after each indicated stimulant ( n = 77 CEFT, n = 79 Fluzone, n = 82 for others). B, Cell type–specific PBMC densities as a percentage of live single cells (bottom) separated by median IFN-β response after TLR1/2 stimulation ( n = 106, PRIME study). A and B, P values are from unpaired t test; mean + SEM is shown. C, Correlation (Spearman r ) of each indicated PBMC (ELISpot), serum (ELISA), or sip-T product metric (CD54 upreg and TNC) output with fold mock IFN-β values after TLR1/2 stimulation; (*) indicates FDR adjusted Q

Year:

2024

Mounting evidence links systemic innate immunity with cancer immune surveillance. In advanced metastatic castration-resistant prostate cancer (mCRPC), Black patients have been found to have increased inflammatory markers and longer survival after sipuleucel-T (sip-T) therapy, an FDA-approved, autologous cell therapy. We hypothesized these differences may be explained by previously reported ancestral differences in pattern recognition receptor signaling, which broadly governs innate inflammation to control adaptive immune cell activation, chemotaxis, and functionality. We discovered that peripheral blood mononuclear cell IFN-β responses to Toll-like receptor 1/2 (TLR1/2), a sensor of bacterial and gut microbiome constituents, associated with significantly longer survival after sip-T therapy in two separate cohorts of men with mCRPC (discovery cohort: n = 106, HR = 0.12; P = 0.019; validation cohort: n = 28, HR P = 0.047). Higher IFN-β induction after TLR1/2 stimulation was associated with lower HRs than biomarkers of vaccine potency and other prognostic factors in mCRPC. TLR1/2-dependent cytokine induction was stronger in Black individuals (1.2-fold higher for IFN-β; P = 0.04) but was associated with survival independently of race or numbers of vaccine-induced tumor antigen–specific T cells. IFN-β responses to TLR1/2 signaling correlated with increased numbers of IFN-γ producing T cells after broad, tumor antigen–independent stimulation. Thus, peripheral innate immunity differs by race, may predict survival after sip-T, and associates with peripheral T-cell functionality in men with mCRPC. Significance: The identification of factors that determine successful cancer immunotherapy, particularly in refractory tumor types like mCRPC, is urgently needed: both to identify patients that may benefit from such therapies and to uncover routes to sensitize patients with cancer to immunotherapy. Our work links functional peripheral immune responses with race and survival after cellular immunotherapy in men with mCRPC.

Year:

2024

TLR1/2 responses associate with post–sip-T survival independent of race and TLR1/2 SNP status. A–C, Survival stratified by race in the merged PRIME and KCI cohorts ( A ), PRIME cohort alone ( B ), or KCI cohort alone ( C ). D and E, Survival of White ( D ) or Black ( E ) patients from the merged (PRIME and KCI) cohorts stratified by respective cohort median (PRIME or KCI) IFN-β induction after TLR1/2 stimulation. F and G, Survival of the PRIME cohort (TLR1 SNP genotyping was not performed in the KCI cohort) stratified by TLR1 602 I/I or I/S vs. TLR1 602 S/S for all races ( F ) or for White patients ( G ). H and I, Survival of patients with TLR1 602 I/I or I/S SNP ( H ) or TLR 602 S/S ( I ) stratified by median IFN-β induction after TLR1/2 stimulation. HRs and 95% CI are from the Mantel–Haenszel test; P values are from the Mantel–Cox log-rank test. See Supplementary Fig. S7 for extended data.

Year:

2024

Stronger IFN-β responses to TLR1/2 stimulation associates with longer survival after sip-T therapy. A, HRs ± 95% CIs from a Cox proportional hazards model comparing induction of each cytokine (fold mock control) after TLR1/2 stimulation with PAM 3 CSK 4 for PRIME cohort (left) or KCI cohort (right) vs. survival; *, P B, Survival of patients tested for TLR1/2 responsiveness stratified by median IFN-β induction for PRIME (left) and KCI (right) cohorts; P values are from Mantel–Cox test, HR and 95% CIs are from Mantel–Haenszel test. C, Mean z -scores normalized for each cytokine and treatment were computed for the combined cohort of patients (PRIME and KCI, n = 108), excluding patients that were censored prior to 1,000 days due to incomplete follow-up. Z -scores for patients surviving >1,000 days ( n = 47) are shown and reflect enrichment/depletion relative to the broader cohort; asterisk indicates FDR adjusted (within each stimulant group) t test Q D, Fold mock treated MFI values for IFN-β after treatment with TLR1/2 stimulation comparing patients surviving 1,000 days from PRIME (top) or KCI (bottom) subcohorts from C ; P values are from unpaired t test and mean + SEM is shown. E, Cox proportional hazards model derived HRs ±95% CI and P values for indicated prognostic features and IFN-β. PSA values were not available for two patients, which were excluded from these analyses ( n = 104). See Supplementary Figs. S2 and S3 for extended data. MFI, mean fluorescence intensity.

Year:

2024

Study design and in vitro responsiveness of PBMCs from patients with mCRPC to PRR agonist prior to sip-T treatment. A, Banked pretreatment PBMCs from the PRIME sip-T discovery cohort ( n = 106) or KCI validation cohort ( n = 28) were subjected to DNA isolation, flow cytometry, and/or testing in an in vitro stimulation assay. Two hundred thousand PBMCs per well were plated and treated with no stimulation (mock) or stimulation (stim) with TLR1/2 (PAM 3 CSK 4 ), TLR4 (LPS), MDA5 (Poly I:C-LyoVec), or T-cell [anti (α)-CD3/28 antibodies] after 24 hours of culture. B–D, Supernatant cytokine release was measured after in vitro stimulation. B, Principal component analyses colored by treatment using raw MFI values for each analyte, each data point represents a single patient. C, Box and whisker plots (Boxes: median ± 25%–75% quartiles, whiskers = range) of fold mock MFI values for each cytokine in the PRIME study ( n = 106), each data point represents a single patient. D, Heatmaps of log (fold mock control) values are shown for the PRIME and KCI (validation) cohorts; asterisks denote FDR adjusted Q t test vs. 0 (no induction). MFI, mean fluorescence intensity.

Year:

2024

Year:

2024

Year:

2022

Collaborators (11)

Andrew Armstrong

Professor

Duke Cancer Institute

UNITED STATES
View details

Ulka Vaishampayan

Professor

University of Michigan

UNITED STATES
View details

Frank Cackowski

Assistant Professor

Karmanos Cancer Institute

UNITED STATES
View details

Michael Brown

Assistant Professor

Duke University

UNITED STATES
View details

Julie Boerner

Associate Professor

Wayne State University

UNITED STATES
View details

Wei Chen

Professor

Wayne State University

UNITED STATES
View details

Elisabeth I. Heath

Wayne State University School of Medicine

UNITED STATES
View details

Sepideh Dolatshahi

Assistant Professor

University of Virginia

UNITED STATES
View details

Archana Thakur

Associate Professor

University of Virginia

UNITED STATES
View details

Michael Gunn

Professor

Duke University

UNITED STATES
View details

Amy Schienschang

University of Virginia

UNITED STATES
View details